Short answer
AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Initial term loans mature July 27, 2033, creating long-dated debt obligations for Avanos Medical.
- This filing includes Item 3.01, an item that often signal trouble.
AVANOS MEDICAL, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Initial term loans mature July 27, 2033, creating long-dated debt obligations for Avanos Medical
- Term SOFR borrowing margin ranges 4.75%-5.25%, indicating elevated financing costs
- Revolving loans priced at term SOFR plus 3.50% or base rate plus 2.50%
- DDTL commitments remain available for 24 months, with 1.00% annual fees on undrawn amounts
- Credit agreement includes leverage-based fees, mandatory prepayments, covenants, and default provisions affecting financial flexibility
Item 1.02 · Termination of a Material Definitive Agreement
- Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing
- Replacement Credit Agreement entered concurrently, indicating post-merger refinancing of existing debt facilities
- JPMorgan Chase Bank served as administrative agent under the terminated facility
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger completed, triggering full replacement of Avanos’s certificate of incorporation and bylaws
- New governing documents mirror Merger Subsidiary’s pre-closing documents, with company-name references updated
- Governance changes may affect shareholder rights and corporate oversight; review Exhibits 3.1 and 3.2 for operative provisions
Item 3.03 · Material Modification to Rights of Security Holders
- Item 3.03 contains no standalone rights modification; it incorporates Items 2.01, 3.01, 5.01 and 5.03
- Investor impact depends on the referenced acquisition, exchange-status, control-change and governance disclosures
Item 5.01 · Changes in Control of Registrant
- Item 5.01 incorporates acquisition, financing, and leadership-change disclosures from Items 2.01, 2.03, and 5.02
- Control-change details require review of the referenced items for transaction structure, debt obligations, and management implications
Item 7.01 · Regulation FD Disclosure
- Merger closing announced jointly by Avanos Medical and Parent
- Transaction completion shifts focus to integration, ownership, and post-merger financial reporting
- Exhibit 99.1 contains the substantive closing details and investor-relevant terms
Item EX-99.1 · Exhibit EX-99.1
- AIP completed Avanos acquisition for approximately $1.272 billion, converting the company into a privately held business
- Avanos shareholders received $25.00 cash per share under the merger agreement
- Avanos common stock ceased trading on the New York Stock Exchange upon closing
- CEO Dave Pacitti remains in place, supporting continuity during AIP’s operational improvement strategy
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
- Item 3.01: Notice of Delisting
- Item 5.02: Departure/Election of Directors or Officers
- Item 5.03: Amendments to Articles of Incorporation or Bylaws
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVANOS MEDICAL, INC. 8-K filings
Get the next AVNS 8-K as it lands
Follow AVNS for push alerts, or ask the research agent what this filing means.